Results 31 to 40 of about 197,154 (267)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy

open access: yesFrontiers in Immunology, 2021
Accumulating evidence demonstrated the crucial role of gut microbiota in many human diseases, including cancer. Checkpoint inhibitor therapy has emerged as a novel treatment and has been clinically accepted as a major therapeutic strategy for cancer. Gut
Jianmin Wu   +6 more
doaj   +1 more source

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature

open access: yesRespiratory Medicine Case Reports, 2019
Immune checkpoint inhibitors are known to cause a variety of immune-related adverse events, including pneumonitis. When symptomatic, treatment typically consists of temporary or permanent cessation of the checkpoint inhibitor and several weeks of ...
Camille R. Petri   +4 more
doaj   +1 more source

Determinants of Resistance to Checkpoint Inhibitors [PDF]

open access: yesInternational Journal of Molecular Sciences, 2020
The development of immune checkpoint inhibitors (ICIs) has drastically altered the landscape of cancer treatment. Since approval of the first ICI for the treatment of advanced melanoma in 2011, several therapeutic agents have been Food and Drug Administration (FDA)-approved for multiple cancers, and hundreds of clinical trials are currently ongoing ...
Linda Tran, Dan Theodorescu
openaire   +2 more sources

Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy

open access: yesPulmonary Circulation, 2020
Immune checkpoint inhibitors successfully treat various malignancies by inducing an immune response to tumor cells. However, their use has been associated with a variety of autoimmune disorders, such as diabetes, hepatitis, and pneumonitis.
Matthew Glick   +5 more
doaj   +1 more source

Gut microbiota shed new light on the management of immune‐related adverse events

open access: yesThoracic Cancer, 2022
Immunotherapy has dramatically revolutionized the therapeutic landscape for patients with cancer. Although immune checkpoint inhibitors are now accepted as effective anticancer therapies, they introduce a novel class of toxicity, termed immune‐related ...
Bei Tan   +8 more
doaj   +1 more source

Bell's palsy during rechallenge of immune checkpoint inhibitor

open access: yesIJU Case Reports, 2023
Introduction The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features ...
Kohji Takemura   +9 more
doaj   +1 more source

Cardio-toxicity of checkpoint inhibitors [PDF]

open access: yesJournal of Thoracic Disease, 2018
Immune checkpoint inhibitors (ICIs) have started revolutionizing the treatment of numerous advanced oncological diseases by restoring immune resistance against cancer cells. ICI-associated cardiac adverse effects are rare, but severe. About 50% of cardiac complications comprise myocarditis with variable clinical presentation and a high rate of fatality.
Oliver J, Müller   +2 more
openaire   +2 more sources

Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor

open access: yesClinical & Translational Immunology, 2022
Objectives Immune checkpoint inhibitors have achieved clinical success in cancer treatment, but this treatment causes immune‐related adverse events, including type 1 diabetes (T1D). Our aim was to test whether a JAK1/JAK2 inhibitor, effective at treating
Tingting Ge   +15 more
doaj   +1 more source

Translational target for checkpoint inhibitors [PDF]

open access: yesNature Reviews Immunology, 2018
Eukaryotic translation initiation complex eIF4F is identified as an upstream regulator of PD-L1 expression and is therefore a promising target for immunotherapy.
openaire   +2 more sources

Immune Checkpoint Inhibitors and Neurotoxicity

open access: yesCurrent Neuropharmacology, 2021
: Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with ...
Zhao, Zhiyi   +4 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy